Generated Narrative

category: Laboratory

code: Therapeutic Implication

derivedFrom: Generated Summary: Laboratory; Genotype display name; effective: 2020-01-01; CYP2C19*2/*2

component

code: Medication assessed [ID]

value: citalopram

component

code: Genetic variation's effect on drug metabolism

value: Poor metabolizer

component

code: Conclusion text

value: For citalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.